Research graph
References from Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial
2026 · External reference
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
10.1016/s0140-6736(24)02808-3 · 2025 · External reference
GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes
2026 · External reference
Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy
10.1038/s41392-024-01931-z · 2024 · External reference
Parkinson disease and the immune system—Associations, mechanisms and therapeutics
10.1038/s41582-020-0344-4 · 2020 · External reference
Glucagon-like peptide-1 receptor agonists and risk of Parkinson's disease in patients with type 2 diabetes: A population-based cohort study
10.1002/mds.29992 · 2024 · External reference
Neuroprotective trials in REM sleep behavior disorder: The way forward becomes clearer
10.1212/wnl.0000000000200235 · 2022 · External reference
Peripheral blood inflammatory cytokines in idiopathic REM sleep behavior disorder
10.1002/mds.27841 · 2019 · External reference
A new metabolic network correlated with olfactory and executive dysfunctions in idiopathic rapid eye movement sleep behavior disorder
10.3988/jcn.2019.15.2.175 · 2019 · External reference
Genetic predictors of GLP1 receptor agonist weight loss and side effects
10.1038/s41586-026-10330-z · 2026 · External reference
